Total submissions: 9
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000637812 | SCV000759291 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2024-12-16 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 1686 of the BRCA1 protein (p.His1686Tyr). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 531444). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 30209399) indicates that this missense variant is expected to disrupt BRCA1 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BRCA1 function (PMID: 30209399). This variant disrupts the p.His1686 amino acid residue in BRCA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12496477, 18757339, 23867111, 25452441, 30209399). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Fulgent Genetics, |
RCV000765358 | SCV000896623 | uncertain significance | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Color Diagnostics, |
RCV001186735 | SCV001353312 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-03-09 | criteria provided, single submitter | clinical testing | This missense variant replaces a conserved histidine with tyrosine at codon 1686 in the BRCT domain of the BRCA1 protein (PMID: 15133503, 18757339). Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant impacts BRCA1 function in haploid cell proliferation in the presence and absence of PARP inhibitor and in a homology-directed DNA repair assay (PMID: 30209399, 31467430). To our knowledge, this variant has not been reported in individuals affected with BRCA1-related disorders in the literature. Different missense variants at this codon, p.His1686Gln and p.His1686Arg, have been reported as disease-causing in ClinVar (variation ID: 55366, 183179). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, additional clinical studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
| All of Us Research Program, |
RCV001076299 | SCV004817599 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-03-23 | criteria provided, single submitter | clinical testing | This missense variant replaces a conserved histidine with tyrosine at codon 1686 in the BRCT domain of the BRCA1 protein (PMID: 15133503, 18757339). Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant impacts BRCA1 function in haploid cell proliferation in the presence and absence of PARP inhibitor and in a homology-directed DNA repair assay (PMID: 30209399, 31467430). To our knowledge, this variant has not been reported in individuals affected with BRCA1-related disorders in the literature. Different missense variants at this codon, p.His1686Gln and p.His1686Arg, have been reported as disease-causing in ClinVar (variation ID: 55366, 183179). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, additional clinical studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
| Lupski Lab, |
RCV001076299 | SCV005402483 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2024-04-12 | criteria provided, single submitter | curation | Each variant was annotated with functional scores from MAVE data which was translated into functional evidence codes. All other evidence codes and combining criteria were adhered to as closely as possible based on the ClinGen VCEP (Variant Curation Expert Panel) gene-specific recommendations. See Supplemental Figure 34 of final paper (Supp Fig. 28 in preprint: doi:10.1101/2024.04.11.24305690) for a table to see which lines of evidence we did not have data for. The ClinGen VCEPs are highly regarded as the gold-standard for gene-specific variant curation and are developed after extensive evaluation of the evidence by clinical and scientific experts for the particular gene to classify genomic variants on a spectrum from pathogenic to benign using the 2015 ACMG/AMP Variant Interpretation Guidelines as a backbone (PMID: 25741868). Reclassification of these VUS variants from gnomAD or All of Us focused only on variants originally prescribed as VUS in ClinVar. To ensure reproducibility, transparency, and increased throughput, all the procedures for annotating variants and assigning evidence codes were codified using Python. All code has been made freely available and is linked in the Code Availability section and all reclassified variants with evidence codes used can be found in Tables S18-19 (preprint: doi:10.1101/2024.04.11.24305690). For the MAVE data, the clinical curation and clinical strength assignment as per the ClinGen recommendations in Brnich et al. (2020) (PMID: 31892348) for or against pathogenicity or benignity of each of these MAVE datasets utilized in this study were previously published in Fayer et al. (2021) (PMID: 34793697).In brief, for BRCA1 variants, if a variant was categorized as FUNC (functional), it was assigned BS3 evidence and no PS3 evidence, whereas if it was categorized as LOF (loss of function), the variant was assigned PS3 evidence and no BS3 evidence. Variants categorized as INT (intermediate) were left unannotated. For the BRCA1 combining criteria, greater than or equal to 1 criteria of strong benign evidence was enough to reclassify the VUS as Likely Benign. This variant GRCh38:17:43067626:G>A was assigned evidence codes ['PS3', 'PP3', 'PM2_Supporting'] and an overall classification of Likely pathogenic |
| Ambry Genetics | RCV001186735 | SCV005547457 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2024-10-09 | criteria provided, single submitter | clinical testing | The p.H1686Y variant (also known as c.5056C>T), located in coding exon 15 of the BRCA1 gene, results from a C to T substitution at nucleotide position 5056. The histidine at codon 1686 is replaced by tyrosine, an amino acid with similar properties. One functional study found that this nucleotide substitution is non-functional in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature, 2018 Oct;562:217-222). Another variant at the same codon, p.H1686R (c.5057A>G), was classified as deleterious based on proliferation assays and cisplatin sensitivity cDNA functional assays in mouse embryonic stem cells (Bouwman P et al. Cancer Discov. 2013 Oct;3(10):1142-55). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Fulgent Genetics, |
RCV005019058 | SCV005647123 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2024-02-08 | criteria provided, single submitter | clinical testing | |
| ARUP Laboratories, |
RCV005231210 | SCV005876932 | likely pathogenic | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | The BRCA1 c.5056C>T; p.His1686Tyr variant (rs1555579648), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 531444). This variant is absent from the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.846). In vitro functional analysis in cell survival assays found this variant to be deleterious (Findlay 2018, Kweon 2020). Additionally, other variants at this codon (p.His1686Arg; p.His1686Gln) have been reported in individuals with breast and ovarian cancer (Couch 2015, Mehrgou 2018, Minucci 2015, Wen 2018). Based on available information, this variant is considered to be likely pathogenic. References: Couch FJ et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015 Feb 1;33(4):304-11. PMID: 25452441. Findlay GM et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018 Oct;562(7726):217-222. PMID: 30209399. Kweon J et al. A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants. Oncogene. 2020 Jan;39(1):30-35. PMID: 31467430. Mehrgou A et al. Investigating of variations in BRCA1 gene in Iranian families with breast cancer. Med J Islam Repub Iran. 2018 Sep 17;32:87. PMID: 30788324. Minucci A et al. Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. Expert Rev Mol Diagn. 2015;15(10):1383-403. PMID: 26306726. Wen WX et al. Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. J Med Genet. 2018 Feb;55(2):97-103. PMID: 28993434. |
| Brotman Baty Institute, |
RCV001076299 | SCV001242019 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |